Valuation: Compass Therapeutics, Inc.

Market Cap 396M 343M 322M 293M 552M 37.79B 560M 3.78B 1.48B 18.92B 1.49B 1.46B 63.09B P/E 2026 *
-4.46x
P/E 2027 * -4.15x
Enterprise Value 246M 213M 200M 182M 343M 23.48B 348M 2.35B 919M 11.76B 924M 904M 39.21B EV / Sales 2026 *
-
EV / Sales 2027 * 11.3x
Free-Float
87.55%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 65 28/05/2024
Director of Finance/CFO 54 09/12/2024
Chief Tech/Sci/R&D Officer 50 01/01/2026
Director TitleAgeSince
Director/Board Member 65 01/01/2014
Director/Board Member 64 01/01/2015
Chairman 61 01/01/2015
Change 5-day change 1-year change 3-year change Capi.($)
-36.48%+32.67% - - 396M
-0.73%+12.52%+74.33%+102.34% 70.51B
+1.60%+1.66%+37.76%+66.48% 54.05B
0.00%+33.91%+8.69%+494.62% 28.95B
-0.61%+12.95%+53.77%+5.42% 24.05B
+0.84%+1.18%-15.97%-13.19% 23.31B
-1.37%+18.52%+255.24%+464.53% 18.67B
+2.21%+7.66%+47.18%-19.64% 18.37B
0.00%+9.69%+31.01%+584.59% 16.1B
-1.57%-10.95%+33.04%+134.73% 12.72B
Average -3.75%+9.21%+58.34%+202.21% 29.64B
Weighted average by Cap. +0.05%+10.12%+56.26%+166.42%

Financials

2026 *2027 *
Net sales - 23.35M 20.23M 18.96M 17.29M 32.51M 2.23B 33.01M 223M 87.15M 1.12B 87.68M 85.77M 3.72B
Net income -93.55M -81.05M -75.94M -69.27M -130M -8.92B -132M -893M -349M -4.47B -351M -344M -14.9B -105M -91.32M -85.56M -78.04M -147M -10.05B -149M -1.01B -393M -5.03B -396M -387M -16.78B
Net Debt -150M -130M -122M -111M -209M -14.31B -212M -1.43B -560M -7.16B -563M -551M -23.89B -133M -115M -108M -98.48M -185M -12.69B -188M -1.27B -496M -6.35B -499M -489M -21.18B
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
2.200USD
Average target price
8.917USD
Spread / Average Target
+305.30%

Quarterly revenue - Rate of surprise